Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Concurrent vs Sequential Rituximab with FND in Indolent Lymphoma
NCT00577993Phase 3Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Mar 1998
- Primary completion
- Aug 2017
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of rituximab in follicular lymphoma (FL), sponsored by University of Texas MD Anderson Cancer Center. Started Mar 1998; status: completed.
02
Drugs
rituximab
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT00577993.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00577993.